https://orcid.org/0000-0003-4427-9413
Peer Review History
| Original SubmissionNovember 3, 2021 |
|---|
|
Dear Dr. Buzon, We are pleased to inform you that your manuscript 'Evaluation of SARS-CoV-2 Entry, Inflammation and New Therapeutics in Human Lung Tissue Cells' has been provisionally accepted for publication in PLOS Pathogens. Before your manuscript can be formally accepted we recommend you to address comments by reviewer # 3. You will also need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests. Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated. IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript. Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS. Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Pathogens. Best regards, Rudra Channappanavar, DVM, Ph.D. Guest Editor PLOS Pathogens Carolina Lopez Section Editor PLOS Pathogens Kasturi Haldar Editor-in-Chief PLOS Pathogens orcid.org/0000-0001-5065-158X Michael Malim Editor-in-Chief PLOS Pathogens *********************************************************** Reviewer Comments (if any, and for reference): Reviewer's Responses to Questions Part I - Summary Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship. Reviewer #1: The revised manuscript is satisfactory and I will recommend it to be accepted. Reviewer #2: (No Response) Reviewer #3: This manuscript evaluates SARS-CoV-2 entry and host response using a a novel human lung tissue model. Strength of this manuscript include, i) a reliable and novel model to rapidly assess the virus infection and therapeutics in human cells/tissue, ii) Offers benefit of assessing epithelial and immune cell cross talk during viral infection, ii) additional advantage of identifying antiviral effects of compounds shown to be not effective in traditional Vero cell culture system. Weakness: some of the results presented are redundant as several previous studies showed similar outcome. Despite this weakness, utility of this model to asses host response and test therapeutic is of interest to broader scientific community. ********** Part II – Major Issues: Key Experiments Required for Acceptance Please use this section to detail the key new experiments or modifications of existing experiments that should be absolutely required to validate study conclusions. Generally, there should be no more than 3 such required experiments or major modifications for a "Major Revision" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend "Reject". Reviewer #1: N/A Reviewer #2: (No Response) Reviewer #3: Although LPS+ IFNg stimulation model is a well established, evaluating inflammation (Figure 6) in HLT/immune cell model following SARS-CoV-2 infection would complement results presented in Figure 1-4. If CoV-2 infection data is available, this reviewer recommends authors to include it with current results. ********** Part III – Minor Issues: Editorial and Data Presentation Modifications Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. Reviewer #1: N/A Reviewer #2: (No Response) Reviewer #3: (No Response) ********** PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Jian Zheng Reviewer #2: Yes: Jincun Zhao Reviewer #3: No |
| Formally Accepted |
|
Dear PhD Buzon, We are delighted to inform you that your manuscript, "Evaluation of SARS-CoV-2 Entry, Inflammation and New Therapeutics in Human Lung Tissue Cells," has been formally accepted for publication in PLOS Pathogens. We have now passed your article onto the PLOS Production Department who will complete the rest of the pre-publication process. All authors will receive a confirmation email upon publication. The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Pearls, Reviews, Opinions, etc...) are generated on a different schedule and may not be made available as quickly. Soon after your final files are uploaded, the early version of your manuscript, if you opted to have an early version of your article, will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers. Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Pathogens. Best regards, Kasturi Haldar Editor-in-Chief PLOS Pathogens orcid.org/0000-0001-5065-158X Michael Malim Editor-in-Chief PLOS Pathogens |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .